A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.
NCT00773526
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
52
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
RO5126766
Sponsor
Hoffmann-La Roche